'Innovation' Meeting Shows FDA-Industry Gap On NDI Guidance Details Remains
Panel discussions and public comments during FDA public meeting show industry sees agency, as it stated in draft NDI notification guidances published in 2011 and 2016, is allowing little room for innovation through making new ingredients available for use in VMS products. FDA says immense growth of the VMS market since DSHEA passed shows numerous products available in US contain substances that haven't been notified to the FDA with proof showing they are dietary ingredients and are safe for use.
You may also be interested in...
Agency "does not believe a hearing is necessary at this time given the other mechanisms at stakeholders’ disposal to interact with FDA on this issue, including submission of comments" for citizen petition CRN submitted on NAC, Andrew Tantillo, acting associate commissioner for legislative affairs, tells Sen. Mike Lee.
Utah Republican Mike Lee suggests attention to N-acetyl-L-cysteine as dietary ingredient FDA has shown for overhauls of its supplement industry regulation, Rx-to-OTC switch process and OTC monograph drug program as well as for cannabinoids and its NDI notification requirement.
ODS Director Steven Tave says violative manufacturing processes and products remain common not because FDA isn’t enforcing its regulations. “I applaud those who stand behind their products, but can you stand with the same conviction behind every product on the market?” he said at regulatory summit organized by trade groups.